Revance to Participate in the 28th Annual Piper Jaffray Healthcare Conference
November 17 2016 - 4:05PM
Business Wire
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
company developing botulinum toxin products for use in aesthetic
and therapeutic indications, today announced that the company will
participate in the 28th Annual Piper Jaffray Healthcare
Conference.
Revance management is scheduled to participate in a fireside
chat discussion on Wednesday, November 30 at 2:30pm ET.
Interested parties can access the live audio webcast for both of
these conferences from the Investor Relations section of the
company's website at www.revance.com. The webcast replay will
be available after the conclusion of the live presentation for
approximately 30 days.
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is
committed to the advancement of remarkable science. The company is
developing a portfolio of products for aesthetic medicine and
underserved therapeutic specialties, including dermatology and
neurology. Revance's science is based upon a proprietary TransMTS®
peptide technology, which when combined with active drug molecules,
may help address current unmet needs. Revance's initial focus is on
developing daxibotulinumtoxinA, the company's highly purified
botulinum toxin, for a broad spectrum of aesthetic and therapeutic
indications, including facial wrinkles and muscle movement
disorders.
The company's lead drug candidate, DaxibotulinumtoxinA for
Injection (RT002), is currently in development for the treatment of
glabellar lines, cervical dystonia and plantar fasciitis and has
the potential to be the first long-acting neurotoxin. The company
holds worldwide rights for all indications of RT002 injectable and
RT001 topical and the pharmaceutical uses of the TransMTS
technology platform. More information on Revance may be found at
www.revance.com.
"Revance Therapeutics", TransMTS®, “Remarkable Science Changes
Everything”, and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161117005815/en/
Investors:Revance TherapeuticsJeanie Herbert, (714)
325-3584jherbert@revance.comorBurns McClellanAmi Bavishi, (212)
213-0006abavishi@burnsmc.comorTrade Media:Nadine Tosk, (504)
453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024